The rationale is that some chemotherapeutic drugs turn non-immunogenic tumour cells to immunogenic, i.e. ICD13,16,61, to present antigens to DCs for recruiting T cells, while anti-PD-1/PD-L1 antibodies disrupt the negative immune-regulation and thus normalise the T cell functions10,59. The gene discussed is PDCD1; the disease is neoplasm.